Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10006676 | 0.85 | HTR2C (0.41) | ALDH1A1POLBPROKR1 | |
| SCHEMBL10006606 | 0.84 | MEN1 (0.39) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL21385821 | 0.81 | ACACB (0.34) | MGLL | |
| SCHEMBL21382139 | 0.80 | RORC (0.39) | — | |
| SCHEMBL21382104 | 0.79 | MGLL (0.41) | MGLL | |
| SCHEMBL21381817 | 0.79 | CACNA1G (0.40) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5224982 | 0.78 | S1PR5 (0.37) | MGLLALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL21382111 | 0.77 | SLC6A9 (0.41) | — | |
| SCHEMBL22638731 | 0.75 | HTR2C (0.42) | ALDH1A1POLBPROKR1 | |
| SCHEMBL15571861 | 0.75 | MAPT (0.43) | ALDH1A1POLBHTTSMN1; SMN2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11939320-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20210171508-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939320-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | MGLL 2627/4885SLC6A3 3310/4885SRD5A1 2427/4885 |
| US-20210171508-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | MGLL 2627/4885SLC6A3 3310/4885SRD5A1 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.